An FDA Panel Voted to Let Pharmacies Sell Peptides the Agency's Own Chemists Say They Cannot Identify.

'When you write a script for TB-500, what form do you think your patients are getting? Does anyone know? I certainly don't' - an FDA scientist, testifying to the committee that voted 8-6-1 to recommend it anyway. The reviewers' note on TB-500: 'No human clinical study identified.'

By Elena Ruiz2026-07-25

The case for the peptides was made in the language of harm reduction. Dr. Haleem Mohammed, a panel member and chief medical officer of Gameday Men's Health, a telehealth men's-clinic chain, put it this way: 'As a physician, I have to make sure that I'm keeping patients as safe as possible' - and, weighing a refusal that would leave patients 'pushing it to the gray market', asked: 'am I doing greater harm?' [1]

It is a real argument. Prohibition does push demand somewhere.

What sits against it is the testimony of the FDA's own staff about what these substances are. On TB-500, agency reviewers wrote: 'No human clinical study identified' [2]. Russell Wesdyk, of the FDA's Center for Drug Evaluation and Research, described the practical problem: 'When you write a script for TB-500, what form do you think your patients are getting? Does anyone know? I certainly don't' [1].

For BPC-157, the entire human efficacy base is a 46-person trial in ulcerative colitis [3] - a different condition from the ones it is marketed for.

The votes reflected the disagreement rather than resolving it. BPC-157, KPV and TB-500 each passed 8-6-1; MOTS-c 7-5-2, epitalon 7-4-1, semax 8-5-1. Emideltide was rejected, 6-7-1 [2].

Elizabeth Rebello of UT MD Anderson, dissenting, named it directly: 'I'm concerned that we're responding to a market-induced demand rather than a decision based in solid science' [3].

The market was watching. Time reported the peptides as a $2.2 billion telehealth opportunity, and Hims and Hers rose more than 10 percent after the BPC-157 vote [3]. The vote is non-binding; the FDA must still review the record and publish proposed rules, which could take up to a year [1].

Sources

Every source is captured on a timestamped archive on the day we cite it, so a cited original cannot be quietly edited or deleted.

[1]
ABC News - FDA advisers narrowly vote to add 6 peptides to compounding list
Read the original Archived
[2]
Healio - FDA committee recommends looser restrictions for several peptides
Read the original Archived
[3]
TIME - FDA committee weighs compounding of peptides
Read the original Archived

the science desk

Elena Ruiz

Reads the study before she shares it, then translates it into plain English with zero tolerance for manufactured doubt. Birdwatcher and tide-pool nerd.